BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29326002)

  • 41. Late Onset Pompe Disease with Novel Mutations and Atypical Phenotypes.
    Chawla T; Preethish-Kumar V; Polavarapu K; Vengalil S; Bardhan M; Puri R; Verma J; Christopher R; Supriya M; Nashi S; Prasad C; Nadeesh B; Nalini A
    J Neuromuscul Dis; 2022; 9(2):261-273. PubMed ID: 34864681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening for late-onset Pompe disease in Finland.
    Palmio J; Auranen M; Kiuru-Enari S; Löfberg M; Bodamer O; Udd B
    Neuromuscul Disord; 2014 Nov; 24(11):982-5. PubMed ID: 25047669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing.
    Lévesque S; Auray-Blais C; Gravel E; Boutin M; Dempsey-Nunez L; Jacques PE; Chenier S; Larue S; Rioux MF; Al-Hertani W; Nadeau A; Mathieu J; Maranda B; Désilets V; Waters PJ; Keutzer J; Austin S; Kishnani P
    Orphanet J Rare Dis; 2016 Jan; 11():8. PubMed ID: 26809617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of acid phosphatase positivity and rimmed vacuoles as useful markers in the diagnosis of adult-onset Pompe disease lacking specific clinical and pathological features.
    Dolfus C; Simon JP; Landemore G; Leroy F; Chapon F
    Folia Neuropathol; 2016; 54(3):295-302. PubMed ID: 27764522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Periodic acid-Schiff staining on resin muscle sections: improvement in the histological diagnosis of late-onset Pompe disease.
    Terracciano C; Rastelli E; Massa R
    Muscle Nerve; 2012 Apr; 45(4):611-2. PubMed ID: 22431097
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology.
    Tehrani KHN; Sakhaeyan E; Sakhaeyan E
    Electron Physician; 2017 Jul; 9(7):4886-4889. PubMed ID: 28894550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
    Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
    Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Late-onset Pompe disease in a 54 year-old sportsman with an episode of syncope: a case report.
    Walczak-Galezewska M; Skrypnik D; Szulinska M; Musialik K; Skrypnik K; Bogdanski P
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3665-3667. PubMed ID: 28925476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myalgic phenotype and preserved muscle strength in adult-onset acid maltase deficiency.
    Jones LK; Liewluck T; Gavrilova RH
    Neuromuscul Disord; 2012 Aug; 22(8):763-6. PubMed ID: 22595200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnosis recommendations for late-onset Pompe disease].
    Brito-Avô L; Alves JD; Costa JM; Valverde A; Santos L; Araújo F; Aguiar P; Marinho A; Oliveira A; Gomes D
    Acta Med Port; 2014; 27(4):525-9. PubMed ID: 25203965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.
    Schaaf GJ; van Gestel TJM; In 't Groen SLM; de Jong B; Boomaars B; Tarallo A; Cardone M; Parenti G; van der Ploeg AT; Pijnappel WWMP
    Acta Neuropathol Commun; 2018 Nov; 6(1):119. PubMed ID: 30404653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel autophagic vacuolar myopathies: Phenotype and genotype features.
    Napolitano F; Terracciano C; Bruno G; De Blasiis P; Lombardi L; Gialluisi A; Gianfrancesco F; De Giovanni D; Tummolo A; Di Iorio G; Limongelli G; Esposito T; Melone MAB; Sampaolo S
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):664-678. PubMed ID: 33393119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.
    Lin N; Huang J; Violante S; Orsini JJ; Caggana M; Hughes EE; Stevens C; DiAntonio L; Chieh Liao H; Hong X; Ghomashchi F; Babu Kumar A; Zhou H; Kornreich R; Wasserstein M; Gelb MH; Yu C
    Clin Chem; 2017 Apr; 63(4):842-851. PubMed ID: 28196920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic tools in late onset Pompe disease (LOPD).
    Musumeci O; Toscano A
    Ann Transl Med; 2019 Jul; 7(13):286. PubMed ID: 31392198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.
    Bali DS; Tolun AA; Goldstein JL; Dai J; Kishnani PS
    Muscle Nerve; 2011 May; 43(5):665-70. PubMed ID: 21484825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Childhood Pompe disease: clinical spectrum and genotype in 31 patients.
    van Capelle CI; van der Meijden JC; van den Hout JM; Jaeken J; Baethmann M; Voit T; Kroos MA; Derks TG; Rubio-Gozalbo ME; Willemsen MA; Lachmann RH; Mengel E; Michelakakis H; de Jongste JC; Reuser AJ; van der Ploeg AT
    Orphanet J Rare Dis; 2016 May; 11(1):65. PubMed ID: 27189384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-risk screening of late-onset Pompe disease: A different early portrait in China.
    Jiao K; Dong J; Luo S; Yu L; Ke Q; Wang Z; Luan X; Zhang X; Guo J; Chen Y; Li X; Tan S; Qian F; Jiang J; Yu X; Yue D; Liu C; Luo L; Li J; Qu Y; Chen L; Tu J; Sun C; Yan C; Song J; Xi J; Lin J; Lu J; Zhao C; Zhu W; Fang Q
    Front Neurol; 2022; 13():965207. PubMed ID: 36237614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.